Filing Flows

Filing Flows › Companies › Autolus Therapeutics › Cash flow

Autolus Therapeutics cash flow, quarter by quarter

Latest: Q2 2026 · from the cash-flow statements filed with the SEC

Free cash flow−$26.0M in Q2 2026 · −$233M over twelve months

Operating cash flow−$25.1M
Capital spending−$913K
Free cash flow−$26.0M
Cash conversion cycle213 days

Analysis

In Q2 2026, Autolus Therapeutics generated −$25.1M of operating cash flow and spent $913K on capital projects, leaving free cash flow of −$26.0M. That is $54.1M more than in Q2 2025 (−$80.1M).

Over the twelve months to Jun 30, 2026, operating cash flow was −$226M; the largest uses were operating cash flow ($226M), other financing ($7.8M), capital spending ($7.1M); besides operations, cash came from other investing ($293M), shares issued ($3K); the cash balance rose by $47.6M.

Operating cash flow was −$25.1M against net income of −$39.1M. The largest differences: receivables −$16.7M, stock-based pay +$4.6M, depreciation & amortization +$2.2M.

Its cash conversion cycle was 213 days (receivables 72 + inventory 148 − payables 7).

Free cash flow

Autolus Therapeutics: free cash flow by quarterAutolus Therapeutics: free cash flow by quarter−$86.3MQ3 2024−$49.0MQ4 2024−$83.8MQ1 2025−$80.1MQ2 2025−$72.3MQ3 2025−$66.4MQ4 2025−$68.0MQ1 2026−$26.0MQ2 2026
Operating cash flow less capital spending.
Autolus Therapeutics: operating cash flow against capital spendingAutolus Therapeutics: operating cash flow against capital spendingOperating cash flowCapital spending−$76.7M$9.6MQ3 2024−$37.9M$11.1MQ4 2024−$75.6M$8.2MQ1 2025−$72.8M$7.3MQ2 2025−$67.9M$4.4MQ3 2025−$67.3M−$885KQ4 2025−$65.3M$2.7MQ1 2026−$25.1M$913KQ2 2026
Latest (Q2 2026): Operating cash flow −$25.1M, Capital spending $913K.

Capital allocation, year by year

Autolus Therapeutics: where the cash came from (up) and went (down), by fiscal yearAutolus Therapeutics: where the cash came from (up) and went (down), by fiscal yearOperating cash flowShares issuedCapital spendingFY2021: Operating cash flow −$118MFY2021: Shares issued $246MFY2021: Capital spending −$8.9M$246MFY2021FY2022: Operating cash flow −$112MFY2022: Shares issued $164MFY2022: Capital spending −$10.8M$164MFY2022FY2023: Operating cash flow −$146MFY2023: Shares issued $27KFY2023: Capital spending −$11.0M$27KFY2023FY2024: Operating cash flow −$206MFY2024: Shares issued $551MFY2024: Capital spending −$22.1M$551MFY2024FY2025: Operating cash flow −$284MFY2025: Capital spending −$19.0MFY2025
Over these 5 years operating cash flow totalled −$866M; the largest uses were operating cash flow ($866M) and capital spending ($71.8M). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$202M
Debtnone
Net cash$202M
Cash runway10 months

Autolus Therapeutics is burning cash: its operations consume cash, a free cash flow of −$233M a year at the current rate against $202M of cash and investments: a runway of about 10 months before any new financing.

Where the cash came from and went

Autolus Therapeutics: sources (+) and uses (−) of cash, Q2 2026Autolus Therapeutics: sources (+) and uses (−) of cash, Q2 2026Other investing$68.8MCash drawn (+) / kept (−)−$40.5MOperating cash flow−$25.1MOther financing−$2.1MCapital spending−$913KExchange rates−$199K
Autolus Therapeutics: sources (+) and uses (−) of cash, TTM to Q2 2026Autolus Therapeutics: sources (+) and uses (−) of cash, TTM to Q2 2026Other investing$293MOperating cash flow−$226MCash drawn (+) / kept (−)−$47.6MOther financing−$7.8MCapital spending−$7.1MExchange rates−$5.2MShares issued$3K

From profit to cash

Autolus Therapeutics: net income to operating cash flow, Q2 2026Autolus Therapeutics: net income to operating cash flow, Q2 2026Net income−$39.1MDepreciation & amortization$2.2MStock-based pay$4.6MReceivables−$16.7MInventory−$1.2MPayables−$667KPrepaid and other assets$30KOperating cash flow−$25.1M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.
QuarterReceivable daysInventory daysPayable daysCash conversion cycle
Q2 2026721487213
Q1 2026891229201

Every quarter

QuarterOperating cash flowCapital spendingShares issuedCash drawn (+) / kept (−)Free cash flow
Q2 2026−$25.1M−$913K—−$40.5M−$26.0M
Q1 2026−$65.3M−$2.7M—−$26.8M−$68.0M
Q4 2025−$67.3M$885K—−$18.0M−$66.4M
Q3 2025−$67.9M−$4.4M—$37.7M−$72.3M
Q2 2025−$72.8M−$7.3M—−$28.1M−$80.1M
Q1 2025−$75.6M−$8.2M—$132M−$83.8M
Q4 2024−$37.9M−$11.1M$7K$430M−$49.0M
Q3 2024−$76.7M−$9.6M$185K$48.4M−$86.3M

Autolus Therapeutics: income statement and cash flow

Autolus Therapeutics, Q2 2026: revenue $45.7M (+118% year over year), operating margin -95.9%. The chart follows the revenue to costs, profit and cash.

Autolus Therapeutics: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.